Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Fig. 3

Efficacy measures through Week 24; a change from baseline HbA1c (%); b change from baseline FPG (mmol/L; to convert to mg/dL multiply mmol/L value by 18); ● omarigliptin, o placebo; based on the longitudinal data analysis model described in the Statistical Analyses Methods section

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us